Schall Law Firm Encourages Shareholders with Losses to Join Securities Fraud Case

The Schall Law Firm is currently inviting shareholders who have experienced losses to take part in a securities fraud case against Applied Therapeutics, Inc. The firm is aiming to hold the company accountable for alleged deceptive practices that resulted in financial harm to investors.

According to a press release issued by The Schall Law Firm, shareholders who purchased Applied Therapeutics securities between November 9, 2020, and July 23, 2021, may be eligible to participate in the securities fraud case. The firm claims that during this time period, Applied Therapeutics made false and misleading statements regarding the results of a drug trial known as “ACTION-Galactosemia.”

The press release states that Applied Therapeutics falsely portrayed the trial’s results, leading investors to believe that the drug in question was more effective than it actually was. As a result, shareholders may have been misled into investing in the company under false pretenses, ultimately suffering financial losses as a result.

The Schall Law Firm is encouraging shareholders who lost money as a result of investing in Applied Therapeutics securities during the specified time frame to join the securities fraud case. By participating in the lawsuit, shareholders may have the opportunity to seek compensation for their losses and hold the company accountable for its alleged misconduct.

In a statement regarding the securities fraud case, The Schall Law Firm emphasized the importance of holding corporations accountable for their actions. The firm expressed its commitment to fighting for justice on behalf of investors who have been wronged by deceptive practices in the marketplace.

Shareholders who wish to join the securities fraud case against Applied Therapeutics, Inc. are encouraged to contact The Schall Law Firm for more information on how to participate. The firm is dedicated to helping investors seek the justice and compensation they deserve in cases of alleged securities fraud and misconduct.